

LE GINECO A L'ASCO 2021 !

GYNECOLOGICAL ORAL SESSION (Lundi 7 juin de 14h à 17h)		
NEOPEMBROV		Abstract # 5500
BOOST		Abstract # 5501
VICTORIA		Abstract # 5507
GYNECOLOGICAL POSTER DISCUSSION		
CHIVA RT – Rad51		Abstract # 5513
PAOLA-1 PFS by disease stage		Abstract # 5514
MILO – Analyse des biomarqueurs		Abstract # 5519
GYNECOLOGICAL POSTER		
KELIM (étude ICON8)		Abstract # 5530
<u>Study in Progress</u> : ROCSAN,ENGOT-cx11, ENGOT-en11		
BREAST POSTER		
PADA1	Exploratory analysis	Abstract # 1070

ORAL PRESENTATION : GYNECOLOGICAL CANCER

<u>NEOPEMBROV</u>	<p>Isabelle Ray-Coquard – Abstract #5500</p> <p><i>Efficacy and safety results from neopembrov study, a randomized phase II trial of neoadjuvant chemotherapy (CT) with or without pembrolizumab (P) followed by interval debulking surgery and standard systemic therapy ± P for advanced high-grade serous carcinoma (HGSC): A GINECO study.</i></p>
<u>BOOST</u>	<p>Jacobus Pfisterer – Abstract #5501</p> <p><i>Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890).</i></p>
<u>VICTORIA</u>	<p>Pierre Etienne Heudel – Abstract #5507</p> <p><i>Victoria: A multicentric, randomized, open-label, phase I/II of mTOR inhibitor (VISTUSERTIB) combined with anastrozole in patients with hormone receptor-positive advanced/metastatic endometrial cancer—A CLIPP program INCA in collaboration with GINECO group</i></p>

POSTER DISCUSSION : GYNECOLOGICAL CANCER

<u>CHIVA RT</u>	<p>Félix Blanc-Durand - Abstract #5513</p> <p><i>Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study</i></p>
<u>PAOLA-1</u>	<p>Patricia Pautier - Abstract #5514</p> <p><i>Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial</i></p>
<u>MILO RT</u>	<p>Rachel N. Grisham – Abstract #5519</p> <p><i>Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).</i></p>

POSTER : GYNECOLOGICAL CANCER

<u>KELIM ICON8</u>	<p>Benoît You - Abstract #5530</p> <p><i>Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial).</i></p>
---------------------------	---

BREAST POSTER SESSION

<u>PADA-1</u>	<p>François Clément Bidart – Abstract #1070</p> <p><i>Efficacy of AI and palbociclib in ER+ HER2- advanced breast cancer patients relapsing during adjuvant tamoxifen: An exploratory analysis of the PADA-1 trial..</i></p>
----------------------	---